Equities Analysts Set Expectations for ARWR Q3 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($0.52) per share for the quarter, down from their previous estimate of ($0.51). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($2.06) EPS.

ARWR has been the subject of several other research reports. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Sanford C. Bernstein reduced their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Piper Sandler lowered their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Hold” and an average target price of $43.33.

Arrowhead Pharmaceuticals Stock Up 9.2 %

ARWR opened at $21.53 on Friday. Arrowhead Pharmaceuticals has a 52 week low of $17.05 and a 52 week high of $36.72. The business has a 50 day moving average price of $20.69 and a two-hundred day moving average price of $22.07. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ARWR. Dimensional Fund Advisors LP grew its stake in Arrowhead Pharmaceuticals by 139.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 145,874 shares of the biotechnology company’s stock valued at $3,791,000 after purchasing an additional 84,867 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of Arrowhead Pharmaceuticals by 23.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 12,751 shares of the biotechnology company’s stock worth $331,000 after buying an additional 2,405 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Arrowhead Pharmaceuticals by 240.5% in the second quarter. Bank of Montreal Can now owns 43,699 shares of the biotechnology company’s stock worth $1,202,000 after buying an additional 30,866 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Arrowhead Pharmaceuticals in the second quarter valued at $9,976,000. Finally, Deerfield Management Company L.P. Series C bought a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at $506,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,850 shares of the company’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the completion of the transaction, the director now owns 36,740 shares in the company, valued at $734,800. This represents a 7.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James C. Hamilton sold 32,729 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now directly owns 272,122 shares in the company, valued at approximately $5,393,458.04. The trade was a 10.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 146,473 shares of company stock valued at $2,937,847. Company insiders own 4.50% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.